Artivion Narrows 2026 Revenue Outlook
The medical device maker raised the low end of its revenue range while lowering the high end, as third-quarter revenue grew 9%.
Updated on Nov. 7, 2026 in Healthcare
Artivion narrowed its 2026 revenue outlook to $484 million to $492 million, down from a previous range of $480 million to $496 million. Third-quarter revenue rose 9% to $123.8 million, while adjusted EBITDA fell 8% to $22.5 million.
Why it matters
The narrower range signals more certainty in Artivion's full-year forecast after a quarter of revenue growth alongside lower profitability. Investors and healthcare industry watchers track such guidance changes as indicators of demand and margin pressure for medical device companies.
Adjusted EBITDA fell 8% to $22.5 million from $24.6 million, and the company now expects 2026 adjusted EBITDA of $93 million to $98 million, including about $8 million in expenses tied to the Endospan acquisition. The company also excludes a $2.3 million reserve for an estimated repayment to the Italian government from its adjusted 2025 revenue.
The players
Artivion
Artivion is a medical device company focused on cardiovascular and aortic surgery products, including stent-graft systems.
The details
Artivion's revised revenue range raised the lower end and lowered the upper end, leaving the midpoint unchanged. The company also reported that the Endospan acquisition, which closed in May 2026, is contributing expenses to its forecast.
Timeline
April 2, 2026: FDA approved the NEXUS aortic-arch stent-graft system.
May 2026: The Endospan acquisition closed.
September 30, 2026: Quarter ended with $123.8 million in revenue.
December 2026: Artivion plans its first surgeon-training event for NEXUS.
January 2027: Planned U.S. commercial launch of NEXUS.
Healthcare Pipeline
Artivion's April 2026 FDA approval of the NEXUS aortic-arch stent-graft system sets up a planned January 2027 U.S. launch that will shape its revenue trajectory. The revised 2026 outlook reflects that product pipeline alongside its recent Endospan acquisition.
For patients needing aortic-arch repair, the NEXUS system's planned January 2027 U.S. launch could expand available treatment options once it reaches hospitals. The timing depends on the surgeon-training schedule and commercial rollout that the company has outlined.
The takeaway
Artivion's narrowed guidance and its pending NEXUS launch show a medical device company balancing near-term margin pressure against a product rollout expected in early 2027. Readers tracking healthcare investment should watch whether the launch timeline holds.
What happens next
Artivion plans to hold its first NEXUS surgeon-training event in December 2026 ahead of the planned January 2027 U.S. commercial launch.
Further reading
For more on the medical device market, explore Healthcare coverage on Wisevoter.
Source note: This article includes information reported by TokenPost.
